soul trial oral semaglutide cardiovascular outcomes 2024 nejm results 2025 Oral Semaglutide's Impact on Cardiovascular Events in Type 2 Diabetes Patients with Cardiovascular and Kidney Disease: SOUL Trial Results Forecasting Trial Milestones: A Predictive

Gln 24 Substituting GLP-1 Ala 30 with Gln decreases the affinity (IC 50 : 0.27 nM1.4 nM) but increases activity (EC 50 : 2.6 nM0.5 nM)

While electrolytes do not directly cause weight loss, they create the conditions that allow your medication to work optimally

Refunds will be issued to the original payment method, minus any applicable restocking, postage, packaging, or administrative fees

Concomitant use of metformin and proton pump inhibitors and vitamin B12 deficiency

These medications have been available for nearly a decade but have only recently gained widespread popularity

The analysts said GLP-1 sales could reach $102 billion by 2030, of which obesity is projected to contribute $41 billion. Two leaders in this field are expected to take roughly 44% and 52% share, respectively, of the global GLP-1 market in 2030. With high financial gain predicted, supply issues have been raised concerning how companies will meet the growing demand